COMMUNIQUÉ DE PRESSE
News
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health to Present Initial Results from the Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) During an April 30 Investor Webcast
Jaguar Health to host investor webcast on crofelemer's impact on MVID and SBS-IF patient experience, with results of investigator-initiated trial by Dr. Miqdady presented at ELITE PED-GI Congress in Abu Dhabi -
COMMUNIQUÉ DE PRESSE
Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval
Mainz Biomed provides Q1 2025 corporate update on FDA premarket approval path, including study enrollment, partnership with Liquid Biosciences and labor team w ag, and product launches. CEO Guido Baechler comments on progress -
-
-
COMMUNIQUÉ DE PRESSE
Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback
Tharimmune, Inc. receives positive FDA feedback on TH104, a buccal film formulation of nalmefene for prophylaxis of opioid exposure in military personnel & first responders -
-
-
